Eggshell Derived Nanohydroxyapatite as a Bone Graft for Intrabony Defects was Evaluated Using (CBCT) - A Randomized Controlled Trial.

IF 0.7 Q4 PHARMACOLOGY & PHARMACY Journal of pharmacy & bioallied sciences Pub Date : 2024-12-01 Epub Date: 2025-01-30 DOI:10.4103/jpbs.jpbs_1041_24

Vishnuvarthan Ganapathy, Anitha Balaji, T S Sampath Kumar, Mohanasatheesh Shanmugam

{"title":"Eggshell Derived Nanohydroxyapatite as a Bone Graft for Intrabony Defects was Evaluated Using (CBCT) - A Randomized Controlled Trial.","authors":"Vishnuvarthan Ganapathy, Anitha Balaji, T S Sampath Kumar, Mohanasatheesh Shanmugam","doi":"10.4103/jpbs.jpbs_1041_24","DOIUrl":null,"url":null,"abstract":"Aim: The study aims to assess the effectiveness of eggshell-derived nanohydroxyapatite (EnHA) as a bone graft material for treating intrabony defects, using cone-beam computed tomography (CBCT) for evaluation.Materials and methods: Ten patients were divided into two groups: Group 1: individuals with 2-wall defects, Group 2: those with 3-wall defects. Follow-up appointments at 1-, 3-, and 6-month intervals included assessments of clinical attachment level (CAL), probing depth (PD), and gingival recession (GR). CBCT scans were conducted pre-operative, immediately post-surgery, and at 1-month, 3-month, and 5-month follow-ups.Results: In both groups, clinical parameters such as CAL, PD, and CBCT measurements reveal significant decreases in CAL and PD values alongside positive trends in CBCT measurements. Additionally, Group 2 exhibited enhancements in periodontal health, suggesting the potential effectiveness of EnHA.Conclusion: EnHA demonstrates potential as a substitute for bone grafting in intrabony defects, showing favourable trends in both clinical and CBCT evaluations during a 6-month observation period.","PeriodicalId":94339,"journal":{"name":"Journal of pharmacy & bioallied sciences","volume":"16 Suppl 5","pages":"S4517-S4521"},"PeriodicalIF":0.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888653/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacy & bioallied sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jpbs.jpbs_1041_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The study aims to assess the effectiveness of eggshell-derived nanohydroxyapatite (EnHA) as a bone graft material for treating intrabony defects, using cone-beam computed tomography (CBCT) for evaluation.

Materials and methods: Ten patients were divided into two groups: Group 1: individuals with 2-wall defects, Group 2: those with 3-wall defects. Follow-up appointments at 1-, 3-, and 6-month intervals included assessments of clinical attachment level (CAL), probing depth (PD), and gingival recession (GR). CBCT scans were conducted pre-operative, immediately post-surgery, and at 1-month, 3-month, and 5-month follow-ups.

Results: In both groups, clinical parameters such as CAL, PD, and CBCT measurements reveal significant decreases in CAL and PD values alongside positive trends in CBCT measurements. Additionally, Group 2 exhibited enhancements in periodontal health, suggesting the potential effectiveness of EnHA.

Conclusion: EnHA demonstrates potential as a substitute for bone grafting in intrabony defects, showing favourable trends in both clinical and CBCT evaluations during a 6-month observation period.

查看原文